环状RNA在乳腺癌中作用的研究进展

doi:10.16352/j.issn.1001-6325.2022.03.007

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (3): 507-511.doi: 10.16352/j.issn.1001-6325.2022.03.007

环状RNA在乳腺癌中作用的研究进展

何啸, 胡为杰, 吕文昌, 任玉萍, 吴敏, 吴毅平, 张奇^*

华中科技大学同济医学院附属同济医院整形美容外科, 湖北武汉 430022

收稿日期:2020-09-15 修回日期:2021-04-06 出版日期:2022-03-05 发布日期:2022-03-04
通讯作者: ^* zhangqi06172@163.com
基金资助:
中国光华科技基金会(2019JZXM001);2020年武汉市科技局应用基础前沿专项(2020020601012241)

Advances on the roles of circular RNA in breast cancer

HE Xiao, HU Wei-jie, LYU Wen-chang, REN Yu-ping, WU Min, WU Yi-ping, ZHANG Qi^*

Department of Plastic Surgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China

Received:2020-09-15 Revised:2021-04-06 Online:2022-03-05 Published:2022-03-04
Contact: ^* zhangqi06172@163.com

摘要/Abstract

摘要： 环状RNA(circRNA)是一类具有环状结构且广泛存在的非编码RNA,具有多样性、特异性、保守性和稳定性等特征。作为新兴的非编码调控分子,circRNA主要通过竞争性内源RNA的机制来调控乳腺癌(BC)细胞增殖和转移,并且参与了多种化学药物治疗耐药、影响疗效。阐明circRNA在BC中的功能与机制,将有助于为BC的诊断和治疗提供新颖有效的策略。

关键词: 乳腺癌, 环状RNA, 竞争性内源RNA, 化学治疗耐药

Abstract: Circular RNA (circRNA) is a kind of non-coding RNA with circular structure and is found in a variety of cell types. CircRNA is characterized by diversity, specificity, conservatism and stability. As an emerging non-coding regulatory molecules, circRNA can regulate the proliferation and metastasis of breast cancer (BC) mainly through the mechanism of competitive endogenous RNA, and is involved in a variety of chemotherapy resistance and affect the efficacy. Elucidating the functions and mechanisms of circRNA in BC may provide novel and effective strategies for the diagnosis and treatment of BC.

Key words: breast cancer, circular RNA, competitive endogenous RNA, chemotherapy resistance

中图分类号:

R737.9

何啸, 胡为杰, 吕文昌, 任玉萍, 吴敏, 吴毅平, 张奇. 环状RNA在乳腺癌中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 507-511.

HE Xiao, HU Wei-jie, LYU Wen-chang, REN Yu-ping, WU Min, WU Yi-ping, ZHANG Qi. Advances on the roles of circular RNA in breast cancer[J]. Basic & Clinical Medicine, 2022, 42(3): 507-511.

参考文献

[1]郑亚男, 李梅, 赵基源. 乳腺癌骨转移分子机制及靶向药物的研究进展[J].基础医学与临床, 2021, 41:433-437.
[2]Narrandes S, Huang SJ, Murphy L, et al. The exploration of contrasting pathways in triple negative breast cancer (TNBC)[J]. BMC Cancer, 2018, 18:22. doi: 10.1186/s12885-017-3939-4.
[3]Hu Q, Zhou T. EIciRNA-mediated gene expression: tunability and bimodality[J]. FEBS Lett, 2018, 592:3460-3471.
[4]Zhang CL, Wu H, Wang YH, et al. Expression patterns of circular RNAs from primary kinase transcripts in the mammary glands of lactating rats[J]. J Breast Cancer, 2015, 18:235-241.
[5]Pagliarini V, Jolly A, Bielli P, et al. Sam68 binds Alu-rich introns in SMN and promotes pre-mRNA circulariza-tion[J]. Nucleic Acids Res, 2020, 48:633-645.
[6]Venø MT, Hansen TB, Venø ST, et al. Spatio-temporal regulation of circular RNA expression during porcine embryonic brain development[J]. Genome Biol, 2015, 16:245. doi: 10.1186/s13059-015-0801-3.
[7]Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the nucleus[J]. Nat Struct Mol Biol, 2015, 22:256-264.
[8]Wesselhoeft RA, Kowalski PS, Anderson GD. Engineer-ing circular RNA for potent and stable translation in eukaryotic cells[J]. Nat Commun, 2018, 9:2629. doi: 10.1038/s41467-018-05096-6.
[9]Wang Q, Li Z, Hu Y, et al. Circ-TFCP2L1 promotes the proliferation and migration of triple negative breast cancer through sponging miR-7 by inhibiting PAK1[J]. J Mammary Gland Biol Neoplasia, 2019, 24:323-331.
[10]Kong Y, Yang L, Wei W, et al. CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression[J]. Epigenomics, 2019, 11:1163-1176.
[11]Yang R, Xing L, Zheng X, et al. The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression[J]. Mol Cancer, 2019, 18:4. doi: 10.1186/s12943-018-0933-7.
[12]Zhang J, Xu HD, Xing XJ, et al. CircRNA-069718 promotes cell proliferation and invasion in triple-negative breast cancer by activating Wnt/β-catenin pathway[J]. Eur Rev Med Pharmacol Sci, 2019, 23:5315-5322.
[13]Wang ST, Liu LB, Li XM, et al. Circ-ITCH regulates triple-negative breast cancer progression through the Wnt/β-catenin pathway[J]. Neoplasma, 2019, 66:232-239.
[14]Ren S, Liu J, Feng Y, et al. Knockdown of circDENND4C inhibits glycolysis, migration and invasion by up-regulating miR-200b/c in breast cancer under hypoxia[J]. J Exp Clin Cancer Res, 2019, 38:388. doi: 10.1186/s13046-019-1398-2.
[15]Liang G, Liu Z, Tan L, et al. HIF1α-associated circdennd4c promotes proliferation of breast cancer cells in hypoxic environment[J]. Anticancer Res, 2017, 37:4337-4343.
[16]Zeng K, He B, Yang BB, et al. The pro-metastasis effect of circANKS1B in breast cancer[J]. Mol Cancer, 2018, 17:160. doi: 10.1186/s12943-018-0914-x.
[17]Xu JH, Wang Y, Xu D. Hsa-circ-001569 is an unfavo-rable prognostic factor and promotes cell prolifera-tion and metastasis by modulating PI3K-AKT pathway in breast cancer[J]. Cancer Biomark, 2019, 25:193-201.
[18]Pan G, Mao A, Liu J, et al. Circular RNA hsa_circ_0061825 (circ-TFF1) contributes to breast cancer progression through targeting miR-326/TFF1 signalling[J]. Cell Prolif, 2020, 53:1-14.
[19]Lin X, Hong S, Chen J, et al. The potential targets for metastases: a study on altered circular RNA profile in breast cancer liver metastases[J]. Epigenomics, 2019, 11:1237-1250.
[20]Liang Y, Song X, Li Y, et al. CircKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer[J]. Oncogene, 2019, 38:6850-6866.
[21]Gao D, Zhang X, Liu B, et al. Screening circular RNA related to chemotherapeutic resistance in breast cancer[J]. Epigenomics, 2017, 9:1175-1188.
[22]Liang Y, Song X, Li Y, et al. Targeting the circBMPR2/miR-553/USP4 axis as a potent therapeutic approach for breast cancer[J]. Mol Ther Nucleic Acids, 2019, 17:347-361.
[23]Sang Y, Chen B, Song X, et al. CircRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p/FOXO3a axis in breast cancer[J]. Mol Ther, 2019, 27:1638-1652.
[24]Uhr K, Sieuwerts AM, de Weerd V, et al. Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1st-line tamoxifen therapy in breast cancer[J]. Sci Rep, 2018, 8:9657. doi: 10.1038/s41598-018-27987-w.
[25]Liu Y, Dong Y, Zhao L, et al. Circular RNA-MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis[J]. Int J Oncol, 2018, 53:1752-1762.

环状RNA在乳腺癌中作用的研究进展

Advances on the roles of circular RNA in breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	苏凌峰, 王虎霞, 王延峰, 宋张骏. 慢性压力对乳腺癌发展的影响[J]. 基础医学与临床, 2024, 44(9): 1303-1307.
[2]	夏雨佳, 杨振丽, 代娣, 刘玉琴. 乳腺癌类器官的培养及鉴定[J]. 基础医学与临床, 2024, 44(9): 1223-1228.
[3]	陆凯, 陆建菊, 郭文利, 黄建棋, 李志华. lncRNA VIM-AS5在人乳腺癌细胞系中的表达及对乳腺癌细胞增殖和迁移的影响[J]. 基础医学与临床, 2024, 44(4): 447-453.
[4]	南璐, 郭梦杰, 高雅楠, 贾红燕. 膜联蛋白A家族成员在乳腺癌中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(3): 393-397.
[5]	依合里曼·买买提, 曹燕珍, 王翠翠, 岳娜, 梁莉萍. PIK3CA突变与乳腺癌临床病理特征及预后的相关性[J]. 基础医学与临床, 2024, 44(3): 303-307.
[6]	李江丽, 孙静, 唐一君, 郭君兰, 陈博, 郭胜男. Circ-DDX5靶向miR-3940抑制人乳腺癌细胞系的增殖和侵袭[J]. 基础医学与临床, 2024, 44(1): 1-7.
[7]	依马木买买提江·阿布拉, 帕哈尔丁·白克热, 易超, 佟庆. 血浆hsa_circ_005230在原发性肝细胞癌诊断和预后评估中的临床价值[J]. 基础医学与临床, 2023, 43(9): 1417-1422.
[8]	陈宁, 彭甜影, 张伟苗, 高亚诺, 李轩, 闫彩珍, 李军霞. 雷公藤甲素与阿霉素联用对人乳腺癌细胞系 MCF-7 的协同促凋亡作用[J]. 基础医学与临床, 2023, 43(8): 1186-1192.
[9]	王继辉, 曹吉烈, 张立军, 张军, 鹿文葆. TARBP2降解AKAP12转录本促进人乳腺癌细胞转移[J]. 基础医学与临床, 2023, 43(8): 1259-1264.
[10]	唐一君, 王文龙, 李江丽, 杨欢, 孙静. LncRNA RP11-686D22.10与乳腺癌患者生存期相关并影响乳腺癌细胞系的增殖和侵袭[J]. 基础医学与临床, 2023, 43(7): 1023-1029.
[11]	郑彬彬, 林淑莹, 李德隆, 陈杰, 黄子成. 环状RNA ATP2B1靶向miR-452-5p降低胃癌细胞系的增殖和侵袭[J]. 基础医学与临床, 2023, 43(6): 882-888.
[12]	高欣, 于永波, 王海存, 姜兴明, 王志东. 环状RNA核受体相互作用蛋白1对肿瘤发生发展的调控机制研究进展[J]. 基础医学与临床, 2023, 43(5): 827-832.
[13]	杨良权, 于淼, 姜茜, 张明慧, 杨海松. miR-504调控蛋白酶体激活因子抑制人乳腺癌细胞系MCF-7增殖及迁移[J]. 基础医学与临床, 2023, 43(1): 95-101.
[14]	王群, 李鑫, 马俊, 李婉明. 核酸适配体W3介导靶向乳腺癌的量子点成像[J]. 基础医学与临床, 2023, 43(1): 76-82.
[15]	张晓雷, 刘静, 李朝萍. Circ_0032821参与索拉非尼抑制乳腺癌细胞系T47D增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(9): 1350-1354.